AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11772282 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimegestone (all doses)
Number of subjects: 96
Study 9256568 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (TNP; 21 mg)
Number of subjects: 424
Study 9256568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 424
Study 9256568 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-enhanced self-help treatment manual
Number of subjects: 424
Study 9256568 — intervention group
Group type: COMPARATOR
Intervention: Self-help treatment manual only
Number of subjects: 424
Study 8209057 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nebulized salbutamol
Number of subjects: 20
Study 8209057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3304324 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon Polymer Foam dressing
Number of subjects: 40
Study 3304324 — intervention group
Group type: COMPARATOR
Intervention: Other non-adherent dressings
Number of subjects: 40
Study 30088679 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision mini-sling (SIMS)
Number of subjects: 130
Study 30088679 — intervention group
Group type: COMPARATOR
Intervention: Transobturator sling (TOT)
Number of subjects: 130
Study 28284575 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus panitumumab
Number of subjects: 100
Study 28284575 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV plus panitumumab
Number of subjects: 100
Study 26221815 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions performed by teachers
Number of subjects: 1316
Study 26221815 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions performed by experts
Number of subjects: 1316
Study 26221815 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lecture interventions
Number of subjects: 1316
Study 26221815 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1316
Study 23789714 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I:E = 1:1
Number of subjects: 100
Study 23789714 — intervention group
Group type: COMPARATOR
Intervention: Group I:E = 1:2
Number of subjects: 100
Study 20628009 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic learning through frequent exposure to collinear contours
Number of subjects: 0
Study 20628009 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific training (bootstrap-based learning) for integrating discontinuities
Number of subjects: 0
Study 18173844 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention consisting of 3 face-to-face and 4 telephone contacts over 6 months, focusing on increasing daily physical activity, improving dietary behaviour, and smoking cessation.
Number of subjects: 692
Study 18173844 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 692
Study 15135594 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate carotid endarterectomy (CEA)
Number of subjects: 3120
Study 15135594 — intervention group
Group type: COMPARATOR
Intervention: Indefinite deferral of CEA
Number of subjects: 3120
Study 11446848 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl‐L‐carnitine 1 g twice daily for 3 months
Number of subjects: 48
Study 11446848 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg twice daily for 3 months
Number of subjects: 48
Study 9712445 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa therapy with 15 microg of diluted buserelin acetate given once a day intranasally
Number of subjects: 44
Study 9712445 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate 50 mg daily by oral administration
Number of subjects: 44
Study 8001518 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat-based RTE cereals
Number of subjects: 8
Study 8001518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat-based RTE cereals
Number of subjects: 8
Study 8001518 — intervention group
Group type: COMPARATOR
Intervention: Rice-based RTE cereal
Number of subjects: 8
Study 8001518 — intervention group
Group type: COMPARATOR
Intervention: Boiled rice
Number of subjects: 8
Study 8001518 — intervention group
Group type: EXPERIMENTAL
Intervention: All products
Number of subjects: 8
Study 3052168 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg kg‐1; n = 12)
Number of subjects: 24
Study 3052168 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (0.3 mg kg‐1; n = 12)
Number of subjects: 24
Study 31079510 — intervention group
Group type: EXPERIMENTAL
Intervention: COPing with and CAring for infants with special needs (COPCA)
Number of subjects: 43
Study 31079510 — intervention group
Group type: COMPARATOR
Intervention: Typical infant physiotherapy
Number of subjects: 43
Study 31101954 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT/PCRT followed by breast-conserving surgery (BCS)
Number of subjects: 107
Study 31101954 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT/PCRT followed by mastectomy (ME)
Number of subjects: 107
Study 28359342 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion as scheduled
Number of subjects: 0
Study 28359342 — intervention group
Group type: COMPARATOR
Intervention: No transfusion
Number of subjects: 0
Study 25528993 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater optimism
Number of subjects: 251
Study 25528993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fatalism
Number of subjects: 251
Study 25528993 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of family history of cancer
Number of subjects: 251
Study 25528993 — intervention group
Group type: EXPERIMENTAL
Intervention: Being female
Number of subjects: 251
Study 25528993 — intervention group
Group type: EXPERIMENTAL
Intervention: Born in the USA
Number of subjects: 251
Study 25528993 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of cancer
Number of subjects: 251
Study 25528993 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 251
Study 25528993 — intervention group
Group type: EXPERIMENTAL
Intervention: Not following the doctor's advice
Number of subjects: 251
Study 25528993 — intervention group
Group type: EXPERIMENTAL
Intervention: Putting off medical problems
Number of subjects: 251
Study 25528993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower optimism
Number of subjects: 251
Study 25528993 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fatalism
Number of subjects: 251
Study 23332501 — intervention group
Group type: EXPERIMENTAL
Intervention: Online course with 3 frontal meetings
Number of subjects: 90
Study 23332501 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face course
Number of subjects: 90
Study 23332501 — intervention group
Group type: EXPERIMENTAL
Intervention: Online course
Number of subjects: 90
Study 22005052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (1.0 mg DMT/kg body weight)
Number of subjects: 10
Study 22005052 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine (20 mg)
Number of subjects: 10
Study 22005052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19780472 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly iron supplementation (ferrous sulphate at 200 mg)
Number of subjects: 0
Study 19780472 — intervention group
Group type: COMPARATOR
Intervention: Control group received once weekly vitamin C at 100 mg
Number of subjects: 0
Study 16829031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally administered salmon calcitonin (200 IU/day)
Number of subjects: 14
Study 16829031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 14521703 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% TCA solution
Number of subjects: 25
Study 14521703 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 25
Study 11255716 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicoidal CT Scan
Number of subjects: 166
Study 11255716 — intervention group
Group type: COMPARATOR
Intervention: Coronary Angiography
Number of subjects: 166
Study 9382539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion chemotherapy with 5-FU + MMC +/- ADR (Group I)
Number of subjects: 52
Study 9382539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion chemotherapy with CDDP + MMC +/- 5-FU (Group II)
Number of subjects: 52
Study 9382539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion chemotherapy with radiotherapy
Number of subjects: 52
Study 9382539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion chemotherapy without radiotherapy
Number of subjects: 52
Study 9382539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion chemotherapy in primary cases
Number of subjects: 52
Study 9382539 — intervention group
Group type: EXPERIMENTAL
Intervention: All cases of intra-arterial infusion chemotherapy
Number of subjects: 52
Study 9382539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion chemotherapy with catheter tip in internal iliac arteries
Number of subjects: 52
Study 8451057 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured preoperative teaching and written pamphlet on PCA
Number of subjects: 0
Study 8451057 — intervention group
Group type: COMPARATOR
Intervention: Usual preoperative preparation provided by the physician
Number of subjects: 0
Study 3530071 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 200 mg orally 3 times a day for 30 days
Number of subjects: 56
Study 3530071 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 200 mg orally for 6 to 18 months
Number of subjects: 56
Study 3530071 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanazolol 2 mg orally 3 times a day for 30 days
Number of subjects: 56
Study 30032196 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy
Number of subjects: 1343
Study 30032196 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone (Control)
Number of subjects: 1343
Study 29316445 — intervention group
Group type: COMPARATOR
Intervention: Platelet-Rich Fibrin (PRF)
Number of subjects: 241
Study 29316445 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (0.2%) plus Platelet-Rich Fibrin (PRF-CHX)
Number of subjects: 241
Study 29316445 — intervention group
Group type: COMPARATOR
Intervention: Non-Platelet-Rich Fibrin (non-PRF)
Number of subjects: 241
Study 29316445 — intervention group
Group type: COMPARATOR
Intervention: Non-Chlorhexidine plus Non-Platelet-Rich Fibrin (non-PRF-CHX)
Number of subjects: 241
Study 27371264 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of MMR vaccine before intramuscular injection of DwPT vaccine
Number of subjects: 70
Study 27371264 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of DwPT vaccine after MMR
Number of subjects: 70
Study 27371264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MMR first and DwPT first)
Number of subjects: 70
Study 24726311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 0
Study 24726311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23114829 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic abutment (test group)
Number of subjects: 20
Study 23114829 — intervention group
Group type: COMPARATOR
Intervention: Conventional healing abutment (control group)
Number of subjects: 20
Study 20660848 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD prescription optimization protocol, patient lists for long-term ASD users, financial compensation for consultations
Number of subjects: 993
Study 20660848 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 993
Study 20660848 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD prescription optimization protocol
Number of subjects: 993
Study 18524761 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of the primary canine only (EG)
Number of subjects: 75
Study 18524761 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of the primary canine and cervical‐pull headgear (EHG)
Number of subjects: 75
Study 18524761 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (CG)
Number of subjects: 75
Study 16298061 — intervention group
Group type: EXPERIMENTAL
Intervention: duloxetine 60 mg QD
Number of subjects: 354
Study 16298061 — intervention group
Group type: EXPERIMENTAL
Intervention: duloxetine 60 mg BID
Number of subjects: 354
Study 16298061 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 354
Study 16298061 — intervention group
Group type: EXPERIMENTAL
Intervention: duloxetine 60 mg QD or duloxetine 60 mg BID
Number of subjects: 354
Study 11881159 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 72
Study 11881159 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training (SIT)
Number of subjects: 72
Study 11881159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Treatment (PE/SIT)
Number of subjects: 72
Study 11881159 — intervention group
Group type: COMPARATOR
Intervention: Wait List Control (WL)
Number of subjects: 72
Study 9798179 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 218
Study 9798179 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 218
Study 9798179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amitriptyline and spinal manipulation
Number of subjects: 218
Study 8566980 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin cream 0.5%
Number of subjects: 269
Study 8566980 — intervention group
Group type: COMPARATOR
Intervention: Podophyllotoxin solution 0.5% (Condyline)
Number of subjects: 269
Study 2698562 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg t.i.d.
Number of subjects: 445
Study 2698562 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 445
Study 1173042 — intervention group
Group type: EXPERIMENTAL
Intervention: Xipamide (4-chloro-5-sulfamoyl-2',6'-salicyloxylidide) administered orally in doses ranging from 0.035 to 0.750 mg/kg body weight
Number of subjects: 0
Study 1173042 — intervention group
Group type: EXPERIMENTAL
Intervention: Xipamide
Number of subjects: 0
Study 1173042 — intervention group
Group type: COMPARATOR
Intervention: Chlortalidone and furosemid
Number of subjects: 0
Study 31951510 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (980 nm)
Number of subjects: 72
Study 31951510 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 72
Study 31951510 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium laser (Er)
Number of subjects: 72
Study 31951510 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Diode (smokers treated with Diode laser)
Number of subjects: 72
Study 31951510 — intervention group
Group type: EXPERIMENTAL
Intervention: S-CO2 (smokers treated with CO2 laser)
Number of subjects: 72
Study 31951510 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Er (smokers treated with Er laser)
Number of subjects: 72
Study 31242596 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed spices (5 g daily)
Number of subjects: 29
Study 31242596 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 29
Study 29187186 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support and Monitoring System (CDSMS) recommendations implemented at physician's discretion
Number of subjects: 439
Study 29187186 — intervention group
Group type: COMPARATOR
Intervention: Current DM treatment standards (Control)
Number of subjects: 439
Study 25921382 — intervention group
Group type: EXPERIMENTAL
Intervention: Capox 50 (capecitabine + oxaliplatin + 50 Gy)
Number of subjects: 598
Study 25921382 — intervention group
Group type: COMPARATOR
Intervention: Cap 45 (capecitabine + 45 Gy)
Number of subjects: 598
Study 25921382 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (201 patients)
Number of subjects: 598
Study 25921382 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical complete response
Number of subjects: 598
Study 25921382 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete response
Number of subjects: 598
Study 23670518 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidopexy
Number of subjects: 130
Study 23670518 — intervention group
Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy
Number of subjects: 130
Study 23670518 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 130
Study 22089042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal lidocaine
Number of subjects: 45
Study 22089042 — intervention group
Group type: COMPARATOR
Intervention: No intradermal lidocaine (Control)
Number of subjects: 45
Study 19220143 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-2 positive at enrollment
Number of subjects: 0
Study 19220143 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-2 positive during follow-up
Number of subjects: 0
Study 19220143 — intervention group
Group type: COMPARATOR
Intervention: HSV-2 negative throughout the study
Number of subjects: 0
Study 19220143 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 0
Study 17126781 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of isobaric ropivacaine (group R; n = 45)
Number of subjects: 90
Study 17126781 — intervention group
Group type: COMPARATOR
Intervention: 7.5 mg of isobaric bupivacaine (group B; n = 45)
Number of subjects: 90
Study 12580661 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Linear Periodization (RLP)
Number of subjects: 60
Study 12580661 — intervention group
Group type: COMPARATOR
Intervention: Linear Periodization (LP)
Number of subjects: 60
Study 12580661 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Undulating Periodization (DUP)
Number of subjects: 60
Study 16510631 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (30 mg daily)
Number of subjects: 602
Study 16510631 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg daily)
Number of subjects: 602
Study 16510631 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and zinc supplementation (30 mg each daily)
Number of subjects: 602
Study 16510631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 10551574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic laryngoscopy (WuScope)
Number of subjects: 87
Study 10551574 — intervention group
Group type: COMPARATOR
Intervention: Conventional laryngoscopy (Macintosh blade)
Number of subjects: 87
Study 8904463 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic techniques
Number of subjects: 8
Study 1878534 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and/or oral doses of sodium dichloroacetate (DCA)
Number of subjects: 0
Study 1878534 — intervention group
Group type: COMPARATOR
Intervention: Oral doses of sodium dichloroacetate (DCA)
Number of subjects: 0
Study 1878534 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dichloroacetate (DCA)
Number of subjects: 0
Study 6193152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin, 1 U/ml
Number of subjects: 40
Study 6193152 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 40
Study 31769551 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring
Number of subjects: 12
Study 28617064 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid plus local anesthetic
Number of subjects: 41
Study 28617064 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic alone (placebo control)
Number of subjects: 41
Study 26680007 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up programme with eight weekly sessions and a booster session a month later.
Number of subjects: 123
Study 26680007 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill-building strategies addressed through the Caregiver Needs and Concerns Checklist (CNCC).
Number of subjects: 123
Study 26680007 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver Needs and Concerns Checklist (CNCC) used to identify and prioritise needs.
Number of subjects: 123
Study 25118121 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural cardiopulmonary instability and adverse events (IAE)
Number of subjects: 3602
Study 25118121 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-balloon time (DBT) <99 minutes
Number of subjects: 3602
Study 21699627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole prolonged release (2-24 mg/day)
Number of subjects: 198
Study 21699627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 21699627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole prolonged release
Number of subjects: 198
Study 19284072 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) with bare metal stents in ARTS I
Number of subjects: 0
Study 19284072 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG) surgery in ARTS I
Number of subjects: 0
Study 19284072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypher stent implantation in ARTS II
Number of subjects: 0
Study 19284072 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of genders in ARTS II
Number of subjects: 0
Study 17763582 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release
Number of subjects: 62
Study 17763582 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release
Number of subjects: 62
Study 15255442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized freeze-dried platelet derived preparation
Number of subjects: 28
Study 15255442 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 28
Study 11988802 — intervention group
Group type: EXPERIMENTAL
Intervention: LapSim training (2 hours per week for 5 weeks)
Number of subjects: 24
Study 11988802 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study 9613683 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 5 microg/kg/dy after intensive sequential chemotherapy
Number of subjects: 46
Study 9613683 — intervention group
Group type: COMPARATOR
Intervention: Control group (no filgrastim)
Number of subjects: 46
Study 7718097 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic leukocyte immunization
Number of subjects: 0